A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes

被引：0
|
作者：
Wu, Anfan
List, Alan
Lush, Richard
Bretz, Kelly
Knight, Robert
Lau, Henry
Zeldis, Jerry
机构：
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4854
引用
收藏
页码：299B / 299B
页数：1
相关论文
共 50 条
  • [21] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Harada, Hironori
    Shibayama, Hirohiko
    Jang, Jun Ho
    Shimazaki, Ryutaro
    Mitani, Kinuko
    Sawada, Kenichi
    Kim, Hyeoung-Joon
    BLOOD, 2014, 124 (21)
  • [22] Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion
    Syed, Yahiya Y.
    Scott, Lesley J.
    DRUGS, 2013, 73 (11) : 1183 - 1196
  • [23] Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion
    Yahiya Y. Syed
    Lesley J. Scott
    Drugs, 2013, 73 : 1183 - 1196
  • [24] Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    List, Alan F.
    Fenaux, Pierre
    Sogrue, Mary M.
    BLOOD, 2015, 126 (23)
  • [25] Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: Results from a randomized clinical trial
    Revicki, Dennis A.
    Brandenburg, Nancy A.
    Muus, Petra
    Yu, Ren
    Knight, Robert
    Fenaux, Pierre
    LEUKEMIA RESEARCH, 2013, 37 (03) : 259 - 265
  • [26] Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload
    Ivars, David
    Teresa Orero, Maria
    Javier, Karla
    Diaz-Vico, Laura
    Luis Garcia-Gimenez, Jose
    Mena, Salvador
    Tormos, Carmen
    Egea, Mercedes
    Luis Perez, Pedro
    Arrizabalaga, Beatriz
    Angeles Ruiz, Maria
    Yague, Nuria
    Tormo, Mar
    Sancho-Tello, Reyes
    Gomes, Angela
    Alguero, Carmen
    Enrique O'Connor, Jose
    Saez, Guillermo T.
    Carbonell, Felix
    Collado, Rosa
    CLINICAL BIOCHEMISTRY, 2017, 50 (16-17) : 911 - 917
  • [27] A Phase II/III Trial of Oral Azacitidine (Oral-AZA) in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Fenaux, Pierre
    Suzuki, Takahiro
    Sekeres, Mikkael A.
    He, Jun
    Barkalifa, Ronit
    Vigil, Carlos E.
    Prebet, Thomas
    Komrokji, Rami
    Giagounidis, Aristoteles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S364 - S364
  • [28] Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Estrov, Zeev
    Godley, Lucy
    Gabrail, Nashat Y.
    Berdeja, Jesus G.
    Nadeem, Ahmed
    Stein, Karen
    Noble, Yvonne
    Kassalow, Laurent
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1628 - 1629
  • [29] Discontinuation of Lenalidomide in Patients with Transfusion-Dependent Low- and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5q): Sustained Remissions, but Not Cure
    Giagounidis, Aristoteles
    Goehring, Gudrun
    Haase, Sabine
    Aul, Carlo
    Schlegelberger, Brigitte
    Kuendgen, Andrea
    Herbst, Regina
    Ehninger, Gerhard
    Platzbecker, Uwe
    BLOOD, 2009, 114 (22) : 1464 - 1465
  • [30] Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure
    Jabbour, Elias J.
    Garcia-Manero, Guillermo
    Strati, Paolo
    Mishra, Asmita
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Kadia, Tapan
    Daver, Naval
    O'Brien, Susan
    Steensma, David P.
    Sekeres, Mikkael A.
    Gore, Steven D.
    Dezern, Amy
    Roboz, Gail J.
    List, Alan F.
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    CANCER, 2015, 121 (06) : 876 - 882
12345